Table 2 Demographic and clinical data of critically ill patients
Variable (unit) | Total n = 16 | LGV group n = 8 | HGV group n = 8 |
|---|---|---|---|
Age (years) | 58 (51–71) | 68 (52–76) | 54 (51–64) |
Body mass index | 29 (25–34) | 32 (24–33) | 27 (25–35) |
Sex—men (%) | 44 | 13 | 75 |
Interval from admission to study (days) | 5 (3–5) | 4 (3–5) | 5 (5–5) |
Interval from MV start to study (days) | 4.5 (3–5) | 3.5 (3–5,3) | 5 (4–5) |
APACHE II score | 35 (23–39) | 35 (24–39) | 33 (21–39) |
SOFA score on the day of the study | 11 (8–14) | 10 (7–11) | 14 (11–15) |
Number of days in the ICU (days) | 11 (14–19) | 13 (11–19) | 14 (12–18) |
Duration of hospitalization (days) | 26 (16–27) | 24 (17–29) | 26 (16–27) |
ICU mortality (%) | 25 | 25 | 25 |
Hospitalization mortality (%) | 44 | 50 | 38 |
GRV 24 h before study (mL) | 345 (28–630) | 25 (8–68) | 630 (627–985) |
GRV single measurement during the study (mL) | 30 (18–90) | 15 (0–20) | 90 (88–200) |
Mean arterial pressure (mmHg) | 92 (85–100) | 94 (88–99) | 90 (85–100) |
Heart rate (beats/minute) | 84 (74–104) | 93 (79–103) | 77 (71–100) |
Intraabdominal pressure (mmHg) | 10 (7–17) | 15,5 (13–18) | 7 (7–10) |
Body temperature (°C) | 37 (36–37) | 37 (36–37) | 36 (36–37) |
Number of clinical interferences | 1 (0–3) | 2 (1–3) | 1 (0–2) |
Noradrenalin use during study (%) | 31 | 25 | 38 |
Betablockers use during study (%) | 6 | 13 | 0 |
Propofol use during study (%) | 31 | 13 | 50 |
Sufentanil use during study (%) | 56 | 38 | 75 |
Blood glucose (mmol/L) | 10 (9–13) | 10 (9–14) | 11 (10–12) |
Arterial lactate (mmol/L) | 1,3 (0,8–1,7) | 1,7 (1,4–2) | 0,8 (0,8–1,3) |
Hemoglobin (g/L) | 102 (93–110) | 104 (98–112) | 98 (93–103) |
C-reactive protein (mg/L) | 72 (44–176) | 68 (17–191) | 72 (70–176) |